Latest Market Reports

There has been an increase in focus on maintaining an infection-free surgical environment in developing countries of Asia Pacific, especially China and India. Growing recognition of Asia Pacific as a medical tourism destination, in tandem with increasing focus on the quality of healthcare services, is likely to enhance the regional value of the back table and cart covers market.

For detailed insights on enhancing your product footprint, request for a sample here- https://www.factmr.com/connectus/sample?flag=S&rep_id=4357

A study published by Fact.MR with incisive data and analytics portends that by 2027, Asia Pacific would outperform North America to become the second-most attractive back table and cart covers market. The pole position of Europe will remain powered by a cohort of factors, including a surge in the number of hospitals, introduction of medical insurance plans, and magnified focus on hygienic healthcare conditions. However, volatility in raw material prices and stringent regulatory scenario regarding medical waste would result in sluggish growth, with the back table and cart covers market projected to witness a CAGR of 2.8% during the forecast period (2020-2027).

Key Highlights of Back Table and Cart Covers Market Study

• Increasing waste management concerns regarding disposable back table and cart covers that are manufactured using materials such as polyethylene, polypropylene, and polyester could downgrade the marketability of manufacturers.
• Demand for cart covers is anticipated to outdo that of back table covers during the forecast period, owing to their extensive application in protecting doctors, patients, and other medical professionals from viral, bacterial, and fungal infection. By 2027, cart covers are projected to account for 42% of share of the back table and cart covers market, up from 40% in 2019.

Need more information about Report Methodology? Click here- https://www.factmr.com/connectus/sample?flag=RM&rep_id=4357

• Contribution of hospitals and diagnostic centres to the overall market share will remain more than the collective share of academic & research institutes and small-scale medical centres during the forecast period. The fact that hospitals and diagnostic centres are deemed key surgical centres is expected to drive the high sales of back table and cart covers.
• Technological advancements made towards the development of materials with utmost efficacy by intensifying focus on lightweight, optimum comfort, fluid absorbance capacity, and anti-fungal properties is likely to resonate well with end users.

A senior market consultant at Fact.MR opines that, “Investments made towards the development of reusable covers will render high returns for players in the back table and cart covers market. Healthcare institutions are actively partaking in the shift from disposable covers towards reusable ones, considering the long-term cost-saving benefits offered by reusable supplies.”

Strategic Expansion to Regions with High Infection Potential to Augur Well

While mergers and acquisitions remain conventional strategies of players operating in the back table and cart covers market, other winning imperatives that they can adopt are strategic expansion, distribution partnerships, and product differentiation. A key player in the back table and cart covers market—Medline Industries—focuses on the strategic expansion of its business operations in regions with high cases of infections, especially the Middle East and Africa and Asia Pacific.

Distribution agreements are an integral part of the business strategy of manufacturers to target remote regions, and online sales channels are emerging as prominent distribution channels with low operational costs. However, players adopting a differentiation strategy hold a distinguished position in the back table and cart covers market, as end users seek materials that offer high resistance against heat, water, tear, stain, odour, mildew, and flames. Besides this, manufacturers are also striving to foster improvements in the permeability, durability, and strength of drapes, back table covers, and cart covers, to increase the exclusiveness of their portfolios.

Full Access of this Exclusive Report is Available at- https://www.factmr.com/checkout/4357/S

Find More Valuable Insights on Back Table and Cart Covers Market

Fact.MR, in its new offering, brings to the fore an unbiased analysis of the global back table and cart covers market, presenting historical demand data (2017-2019), and forecast statistics for the period of 2020-2027. The study divulges compelling insights on the back table and cart covers market on the basis of product (back table covers and cart covers), usage (disposable covers and reusable covers), and end user (hospitals and diagnostic centres, academic & research institutes, and others), across five major regions.

About Fact.MR

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in the US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have in our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.

Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
E: sales@factmr.com
Website: https://www.factmr.com

Rapid emergence of biologics presents new commercial opportunities for players in the arthritis therapeutics market. The adoption of biologic drugs is high, especially in developed countries of North America, Europe, and Asia Pacific, given the influence of favourable reimbursement scenarios that cushion the high cost.

For detailed insights on enhancing your product footprint, request for a sample here- https://www.factmr.com/connectus/sample?flag=S&rep_id=4355

In North America and Europe, the presence of public and private medical insurance plans encourages patients to avail quality healthcare. However, in developing countries of Asia Pacific, the out-of-pocket payment model is dominant in the healthcare industry, which is leading to sluggish growth of the arthritis therapeutics market in India and China. In addition, the penetration of generic drugs is high in developing countries of Asia Pacific, owing to their competitive prices.

A comprehensive study published by Fact.MR projects the arthritis therapeutics market to register 7.3% growth in 2020, over 2019.

Key Takeaways of Arthritis Therapeutics Market Study

• Constant rise in the prices of popular drugs such as Humira and Enbrel could shift the focus of patients towards complementary and alternative therapies, thereby narrowing the growth of the arthritis therapeutics market. The impact of this trend will be relatively high in developing countries of Asia Pacific such as India and China, as these regions are characterized by high inclination towards natural and herbal therapies.
• Patent expiration of blockbuster drugs in the arthritis therapeutics market are pushing manufacturers to increase investments towards the development of effective drugs, which is projected to fuel the advancements of biosimilar products.

Need more information about Report Methodology? Click here- https://www.factmr.com/connectus/sample?flag=RM&rep_id=4355

• High precision of drugs offered by arthritis therapeutics is projected to maintain patients’ inclination towards parenteral route of administration during the forecast period.
• In 2020, retail pharmacies are projected to account for 79% of the total sales of arthritis therapeutics, as the high concentration of this channels across key locations makes it convenient for patients to purchase the required drugs. However, sales through online pharmacies will gain traction, owing to attractive discounts and convenience offered.

A key opinion leader at Fact.MR portends, “Demand for interleukin inhibitors is outperforming TNF inhibitors in terms of efficacy. In future, with effective marketing efforts by manufacturers, patients will turn more receptive to these novel biologic products.”

Full Access of this Exclusive Report is Available at- https://www.factmr.com/checkout/4355/S

R&D Remains Key Strength of Global Players; Regional Players Excel through Robust Distribution Networks

The arthritis therapeutics market, characterized by consolidation, is dominated by AbbVie Inc., Johnson & Johnson, Amgen Inc., and Novartis Inc. Development of blockbuster drugs enables these leading players to gain an edge over regional and local players. For instance, 33% of share in the arthritis therapeutics market accounted by AbbVie is attributable to its flagship product – Humira, which recorded sales corresponding to a value of US$ 20 Bn in 2018.

On similar lines, Johnson & Johnson strives to diversify its product portfolio through the introduction of effective therapeutics. The company is highly recognized for the launch of Simponi, Tremfya, and Stelara. Distribution channels remain the key strength of regional players. For instance, Eli Lily and Company offers most of its products around the world, and executes effective marketing strategies to position its products in various countries to meet unmet local needs.

Find More Valuable Insights on Arthritis Therapeutics Market

Fact.MR, in its new offering, brings to the fore an unbiased analysis of the global arthritis therapeutics market, presenting historical demand data (2017-2019), and forecast statistics for the period of 2020-2027. The study divulges compelling insights on the arthritis therapeutics market on the basis of type (rheumatoid arthritis, gout, psoriatic arthritis, osteoarthritis, and others), drug class (TNF inhibitors, interleukin inhibitors, NSAIDs, corticosteroids, xanthine oxidase inhibitors, and others), route of administration (parenteral, topical, and oral), and distribution channel (online pharmacies, hospital pharmacies, and retail pharmacies), across five major regions.

About Fact.MR

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in the US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have in our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.

Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
E: sales@factmr.com
Website: https://www.factmr.com

Increasing prevalence of various gynecological disorders requiring early diagnostic treatment is prompting demand for hysteroscopy systems. Given its minimal invasiveness, relatively compact form, and ease-of-use, in-office hysteroscopy is being increasingly preferred over operating room hysteroscopy. For instance, female sterilization conventionally performed using devices such as Essure can now be performed in gynecological clinics using hysteroscopy systems.

For detailed insights on enhancing your product footprint, request for a sample here- https://www.factmr.com/connectus/sample?flag=S&rep_id=2577

On the back of these factors, Fact.MR projects the global hysteroscopy systems market to be valued at US$ 440 Mn in 2019, and witness a CAGR of 5% during the forecast period (2019 – 2029).

Key Takeaways of Hysteroscopy Systems Market Study

• An increase in ageing female population and prevalence of gynecological diseases such as infertility, uterine cancers, uterine fibroids and polycystic ovarian disease (PCOD) have created an uptick in the demand for hysteroscopy systems.
• Medicare in North America is encouraging office-based hysteroscopy by increasing its reimbursement amount and at the same time declining physician reimbursement for in-hospital and outpatient surgery center cases. This is expected to provide lucrative opportunities for manufacturers of office-based hysteroscopy systems.
• Hospitals are expected to be the dominant end user in the hysteroscopy systems market.
• Refinement in optical fiber technology and development of new surgical accessories in the past decade have had a significant impact on the quality of visual resolution and techniques for surgeries using hysteroscopy. Increasing focus on development of new and advanced hysteroscopy systems such as disposable or single-use hysteroscopy systems is expected to bolster market growth.

Need more information about Report Methodology? Click here- https://www.factmr.com/connectus/sample?flag=RM&rep_id=2577

“Technological advancements have led to development of single-use hysteroscopy systems and handheld hysteroscopy systems. These would be widely preferred especially in emerging economies with relatively poor healthcare infrastructure, creating new growth avenues” says a Fact.MR Analyst

Single-Use Hysteroscopes Gather Momentum, Outpace Endoscopic Devices

Durability of endoscopic devices has been a concern since its introduction. One of the most common problems encountered while operating these devices is obscured image due to seepage of fluid in optical channels or breaking and stretching of cables. Technologically advanced endoscopes and reusable hysteroscopes have not completely been able to resolve this issue.

Single-use devices not only address the problem of obscured images, but also reduce the risk of cross-contamination, and maintain performance from procedure to procedure with less time consumption. Meditrina launched Aveta Pearl Hysteroscope, which is the first single-use hysteroscope to include full physician control providing proprietary fluid management and video control function directly on the hysteroscope handle. These advantages over traditional hysteroscopy systems will increase demand for single-use hysteroscopy systems offering lucrative growth opportunities for manufacturers.

Full Access of this Exclusive Report is Available at- https://www.factmr.com/checkout/2577/S

Looking for more information?

The research study on hysteroscopy systems market by Fact.MR incorporates an unbiased assessment of key demand-driving factors and trends which have shaped the landscape of hysteroscopy systems over 2014 – 2018 and includes a detailed assessment of key parameters that are anticipated to exert influence over 2019 – 2029. Market statistics have been presented on the basis of product (hysteroscopes, hysteroscopy fluid management systems, and hysteroscopic tissue removal systems), modality (benchtop systems, standalone systems, and handheld systems), and end user (hospitals, diagnostic laboratories, office-based setting, and ambulatory surgical centers) across seven major regions.

About Fact.MR

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in the US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have in our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.

Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
E: sales@factmr.com
Website: https://www.factmr.com

Recent shift from single dose to double dose apheresis is indicative of the high demand for apheresis procedures among patients suffering from chronic diseases. Leading industry players are taking calculated growth measures to expand application of the therapeutic apheresis procedure, which is currently used as the first line and supportive therapy in the treatment of over 87 diseases, as found by the American Society for Apheresis (ASFA). However, lack of availability of donors and concerns regarding histocompatibility could create negative sentiments among patients, inadvertently impeding revenue potential of the apheresis market to a certain extent. Defying all odds though, the apheresis market is projected to progress at an impressive CAGR of ~10% during the forecast period (2020 – 2025), as noted by Fact.MR in its latest study on the market.

For detailed insights on enhancing your product footprint, request for a sample here- https://www.factmr.com/connectus/sample?flag=S&rep_id=4352

Key Takeaways of Apheresis Market Study

• Double dose apheresis is projected to gain prominence as the standard apheresis procedure in developed countries such as the U.S. Japan, and Germany, given an increase in awareness regarding apheresis procedures, competent plasma separator systems, and favourable reimbursement scenarios.
• Low availability of skilled professionals to perform apheresis procedures, in turn, increases the cost of operations, which could encourage patients to seek alternative treatments. This factor will be more impactful in economically-backward and developing regions, wherein, healthcare quality is still not at par with global standards.
• The popularity of plasmapheresis will remain high through 2027, on the backdrop of the high demand for plasma from pharmaceutical and biotechnology industries for the development of novel therapeutics.

Need more information about Report Methodology? Click here- https://www.factmr.com/connectus/sample?flag=RM&rep_id=4352

• Applications of apheresis procedures in neurology are projected to show a marginal rise during the forecast period, as these procedures are recommended as the first line of treatment for neurological diseases such as Guillain-Barre syndrome (GBS), chronic focal encephalitis, multiple myeloma, and myasthenia gravis.

“Increasing prevalence of leukaemia and autoimmune disorders among children unfolds a new demography for players to cater to in the apheresis market, as a majority of apheresis therapies are only available for adult patients”, opines a senior market consultant at Fact.MR.

High Entry Barrier in Apheresis Market; Competition Continues to Intensify

The competition is high in the apheresis market, and is likely to intensify in the future, as the number of centres offering apheresis procedures is increasing. Cost-competitiveness remains a key strategy to maintain or increase share in the apheresis market. Existing players will witness low competition from new market entrants, as these players are well-established in the apheresis market with sound financial reserves, which enables them to easily scale their position. On the other hand, an entry into the apheresis market means high level of investment, sound technical knowledge, and licensing requirements, which is creating entry barriers for new players.

Full Access of this Exclusive Report is Available at- https://www.factmr.com/checkout/4352/S

The current strategy of players in the apheresis market involves a scramble towards the Asia Pacific and Latin American markets. Besides inorganic growth, players seek market success by maintaining high research & development standards to target multiple applications through their products.

Find More Valuable Insights on Apheresis Market

Fact.MR, in its new offering, brings to the fore an unbiased analysis of the global apheresis market, presenting historical demand data (2015-2019), and forecast statistics for the period of 2020-2025. The study divulges compelling insights on the apheresis market on the basis of end user (hospitals and blood collection centres), technology (centrifugation and membrane filtration), procedure (plasmapheresis, photopheresis, LDL apheresis, plateletpheresis, leukapheresis, erythrocytapheresis, and others), product (devices and disposables), and application (renal diseases, neurology, haematology, cancer, autoimmune diseases, cardiovascular diseases, and others), across five major regions.

About Fact.MR

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in the US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have in our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.

Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
E: sales@factmr.com
Website: https://www.factmr.com

Advanced cancer technologies are making inroads into the anticancer drugs market for the diagnosis and treatment of cancer with minimal invasion. Patients are showing high interest towards advanced therapeutics such as targeted therapy and drugs, on account of their capability to fight specific cancer cells without disrupting the functions of healthy cells. However, the popularity of conventional medicines such as Ayurveda medicines, homeopathic medicines, and other herbal medicines could limit the sales potential of the anticancer drugs market space, especially in Southeast Asia, China, India, and the Middle East & Africa.

For detailed insights on enhancing your product footprint, request for a sample here- https://www.factmr.com/connectus/sample?flag=S&rep_id=4350

All-in-all, market players can look at healthy growth of the landscape, with a CAGR of ~7% during the forecast period (2020-2025), as estimated by an exclusive study published by Fact.MR.

Key Takeaways of Anticancer Drugs Market Study

• Governments and central authorities, especially in developed regions, are supporting research & development activities undertaken by players in the anticancer drugs market, which will strengthen the pipeline for anticancer drugs. For instance, the U.S. government allocates a separate budget for the National Cancer Institute (NCI) – an institute that conducts clinical trials on cancer patients.
• Growing awareness regarding cancer prevention and treatment, on the back of campaigns run by government organizations and NGOs across the world, is projected to encourage people to undergo screening tests.
• Some patients show reluctance towards anticancer drugs, on account of the underlying side-effects associated with their long-term consumption, which is likely to impede the sales prospects of players in the anticancer drugs market during the forecast period.
• Sales of anticancer drugs for the treatment of breast cancer, which is one of the most common cancer types across the world, will remain high during the forecast period. Awareness programs conducted to spread information about breast cancer are likely to create a large patient pool for the anticancer drugs market during the forecast period.

Need more information about Report Methodology? Click here- https://www.factmr.com/connectus/sample?flag=RM&rep_id=4350

A senior market research analyst at Fact.MR opines that, “A shift away from conventional therapies towards targeted therapies will remain crucial for the growth of the anticancer drugs market during the forecast period. In the future, as advanced therapeutics are introduced by market players, the preference for therapies with the least side-effects will be high.”

Prominent Players Seek Market Growth through Co-developing Agreements

The anticancer drugs market is a consolidated landscape, with F. Hoffmann-La Roche Ltd, Eli Lily and Company, Novartis AG, Pfizer, Inc., and CELGENE CORPORATION holding a significant chunk of the market share. Leading players strive to introduce promising cancer treatment approaches to strengthen their product portfolios, and, in turn, achieve orphan status for their drugs. F.Hoffmann-La Roche Ltd took a novel approach of collaboration through the launch of the Immunotherapy Centres of Research Excellence imCORE Network, which brings in experts and leading scientists from across the world to introduce therapeutics with better patient outcomes. However, this player has a relatively low presence in Eastern Europe and the Middle East & Africa as compared to other regions, which could serve as a growth opportunity for its counterparts.

Full Access of this Exclusive Report is Available at- https://www.factmr.com/checkout/4350/S

Prominent and emerging players rely on strategic collaborations and partnerships to share expertise and a gain reciprocal advantage in the anticancer drugs market. For instance, Amgen Inc. is entering into agreements with numerous companies such as AstraZeneca and Astellas Biopharma to co-develop medicines in Japan.

Find More Valuable Insights on Anticancer Drugs Market

Fact.MR, in its new offering, brings to the fore an unbiased analysis of the global anticancer drugs market, presenting historical demand data (2015-2019), and forecast statistics for the period of 2020-2025. The study divulges compelling insights on the anticancer drugs market on the basis of drug type (cytotoxic drugs, targeted drugs, and hormonal drugs), therapy (chemotherapy, immunotherapy, targeted therapy, and others), and cancer type (lung cancer, breast cancer, leukaemia, and colorectal cancer), across five major regions.

About Fact.MR

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in the US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have in our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.

Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
E: sales@factmr.com
Website: https://www.factmr.com

The antibacterial drugs market is encountering numerous challenges, ranging from regulatory barriers, patent expirations, to low returns on investment. Patent expirations of blockbuster drugs are further offering ground to regional and local players to introduce generic drugs, which is hard-hitting the sales of branded drugs. However, rise in public-private funding is projected to underpin the development of novel drugs, thereby strengthening the pipeline for new therapeutics in the antibacterial drugs market. On the backdrop of these influences, a recently published report by Fact.MR portends that, the antibacterial drugs market will expand at a sluggish CAGR of 1.5% during the forecast period (2020-2025).

For detailed insights on enhancing your product footprint, request for a sample here- https://www.factmr.com/connectus/sample?flag=S&rep_id=4340

Key Highlights of Antibacterial Drugs Market Study

• Macrolides are fast-replacing quinolones, on the back of their high efficiency; however, the growing use of β-lactam in parallel to a large number of pipeline drugs in the phase-3 trial stage is expected to retain the lead of this drug class during the forecast period.
• Convenience remains a key determiner when it comes to preferred route of administration. Patients’ proclivity for enteral drugs is projected to increase, on account of oral therapy and relatively safe use than the parenteral route of administration.
• Currently, e-pharmacies witness challenges, such as non-complacency of e-retailers with government regulations, concerns regarding credibility of prescription, drug counterfeiting, and delay in shipping. However, in the future, this distribution channel will remain integral in driving sales from overseas markets.
• Wide availability of over-the-counter (OTC) drugs and generic drugs could limit the penetration of drugs in the Asia Pacific antibacterial drugs market. However, patent expiration of drugs in North America and Europe will also lead to a shift from branded drugs to generic ones, which could prevent the antibacterial drugs market from realizing its true revenue potential.

Need more information about Report Methodology? Click here- https://www.factmr.com/connectus/sample?flag=RM&rep_id=4340

A senior research consultant at Fact.MR foresees, “Numerous branded drugs are on the verge of patent expiry, and there are less number of antibacterial drugs in the pipeline. Regional and local players are developing generic drugs in large quantities to bridge the demand-supply gap, which may lead to low RoI for leading players in the antibacterial drugs market.

Manufacturers Experiment with Route of Administration to Enhance Drug Efficiency

The antibacterial drugs market represents a fragmented landscape, wherein, Bayer AG, Pfizer Inc., Merck Co., Inc., Allergan Inc., and GlaxoSmithKline PLC occupy leading positions. Pharmaceutical companies are experimenting with the route of administration to enhance the effectiveness of drugs. For instance, the Amikacin inhaler is available as a nanoscale liposomal formulation, which is effective for the treatment of chronic P. aeruginosa lung infections in cystic fibrosis.

Full Access of this Exclusive Report is Available at- https://www.factmr.com/checkout/4340/S

Besides this, the governments of numerous countries, especially developed countries, are playing an active role in empowering drug manufacturers to introduce new formulations. An example of this can be taken from the CDER Antibacterial Drug Development Task Force created by the U.S. Food and Drug Administration. The foundation of this unit lies in extending government support towards the development of new antibacterial drugs.

Collaborations of players in the antibacterial drugs market with academia, biotech companies, regulatory authorities, and pharmaceutical companies are also seen as a strategic move to gain the reciprocal advantage of technology and expertise.

Find More Valuable Insights on Antibacterial Drugs Market

Fact.MR, in its new offering, brings to the fore an unbiased analysis of the global antibacterial drugs market, presenting historical demand data (2015-2019), and forecast statistics for the period of 2020-2025. The study divulges compelling insights on the antibacterial drugs market on the basis of drug class (β-lactams, quinolones, macrolides, tetracycline, aminoglycosides, sulphonamide, phenicols, and others), route of administration (enteral, parenteral, and others (inhalation, topical, etc.)), and distribution channel (hospital pharmacies, drug stores and retail pharmacies, and online pharmacies), across five major regions.

About Fact.MR

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in the US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have in our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.

Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
E: sales@factmr.com
Website: https://www.factmr.com

Increasing preference for minimally-invasive surgeries along with rise in the number of ambulatory surgical procedures, inadvertently creates a highly conducive environment for the growth of the anticoagulant reversal drugs market. Another significant boost to the sales of anticoagulant reversal drugs can be attributed to their new technology add-on payment (NTAP) status, as designated by the U.S. Following this, patients are accessing these drugs along with Medicare/Medicaid plans in hospital settings, which is projected to generate significant sales from hospital pharmacies.

For detailed insights on enhancing your product footprint, request for a sample here- https://www.factmr.com/connectus/sample?flag=S&rep_id=4338

Given the relevance of these dynamics, a comprehensive study published by Fact.MR foresees that, the global anticoagulant reversal drugs market will expand at a staggering CAGR of ~16% during the forecast period (2020-2026).

Key Highlights of Anticoagulant Reversal Drugs Market Study

• Launch of novel drugs with relatively high efficiency and better recovery times could overshadow the popularity of conventional drugs such as prothrombin complex concentrates and vitamin K.
• High prices of patented drugs could impede the penetration of anticoagulant reversal drugs, especially in developing economies. In developed countries of North America and Europe, favourable reimbursement scenarios are increasing patients’ reliance on effective anticoagulant reversal drugs.
• The designation of Andexxa as an orphan drug by the U.S. Food and Drug Administration is anticipated to influence the infiltration rate of this drug during the forecast period (2020-2026). The fast-track approval of Andexxa will meet unmet clinical needs, thereby promising lucrative opportunities for players in the anticoagulant reversal drugs market.

Need more information about Report Methodology? Click here- https://www.factmr.com/connectus/sample?flag=RM&rep_id=4338

• Manufacturers in the anticoagulant reversal drugs market are capitalizing on profitable opportunities present in developed and developing countries of Asia Pacific to target a relatively wide patient pool and enhance their market exposure. For instance, a key player—Portola Pharmaceuticals—entered into a licensing partnership with Pfizer and BMS. According to the contract, both these partner companies will have commercial rights of Andexxa in Japan.
• Hospital pharmacies are projected to generate the highest sales in the anticoagulant reversal drugs market during the forecast period. Growing number of patient admissions in hospitals and the need to control bleeding during surgeries are projected to create enormous sales opportunities for hospital pharmacies.

“Collectively, Idarucizumab and Andexxa hold a majority share in the anticoagulant reversal drugs market, owing to their utmost efficiency. However, the ‘orphan drug’ status of Andexxa could give it an edge over other drugs”, foresees a seasoned analyst at Fact.MR.

Full Access of this Exclusive Report is Available at- https://www.factmr.com/checkout/4338/S

Market Majors Focus on Branded Drugs, Regional Players Produce Generic Drugs

Boehringer Ingelheim GmbH, CSL Limited, and Portola Pharmaceuticals, Inc. dominate the anticoagulant reversal drug market. These players rely on research & development activities to introduce a range of effective drugs to enrich their portfolio. Expansion of production facilities, in turn, remains one of the top agendas of these players in the anticoagulant reversal drugs market. For example, market leader—Boehringer Ingelheim GmbH—operates through 29 production facilities located across nine countries, which are categorized into Biopharmaceuticals, Animal Health, and Human Pharmaceuticals. However, these leading players produce drugs in only one drug class, which is generally Prothrombin Complex Concentrate.

In stark contrast to THE strategies adopted by leading players in the anticoagulant reversal drugs market, regional and local players strive to consolidate their market position by increasing investments towards THE production of generic versions of branded drugs. For instance, Amneal Pharmaceutical Inc. announced the launch of Phytonadione tablets, a generic version of Mephyton.

Find More Valuable Insights on Anticoagulant Reversal Drugs Market

Fact.MR, in its new offering, brings to the fore an unbiased analysis of the global anticoagulant reversal drugs market, presenting historical demand data (2016-2019), and forecast statistics for the period of 2020-2026. The study divulges compelling insights on the anticoagulant reversal drugs market on the basis of Product (Prothrombin Complex Concentrates, Andexxa, Vitamin K, Protamine, Tranexamic Acid, Idarucizumab, and Others) and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), across five major regions.

About Fact.MR

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in the US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have in our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.

Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
E: sales@factmr.com
Website: https://www.factmr.com

In recent times, the ‘salon at home’ culture has been gaining wide acceptance, which is projected to arise as a crucial end user in the anti-aging and anti-wrinkle products market. The advent of brand-owned salons in key localities is a significant parameter driving the sales of anti-aging and anti-wrinkle products. On the demand side, consumers, especially females, are increasingly conscious about their looks, which is encouraging them to try out various creams and serums to achieve flawless skin. The proclivity of consumers for premium and branded products is growing, powered by an increase in their discretionary spending. However, as cases of the side effects of these products are coming to light, a shift has been witnessed in the consumption pattern towards products with organic and natural ingredients, which is also indicative of the shift in manufacturers’ production strategy.

For detailed insights on enhancing your product footprint, request for a sample here- https://www.factmr.com/connectus/sample?flag=S&rep_id=4337

Given the influence of the changing dynamics, an exclusive study published by Fact.MR foresees a moderate growth pace of the anti-aging and anti-wrinkle products market, at an estimated CAGR of 6% during the forecast period (2020-2027).

Key Takeaways of Anti-aging and Anti-wrinkle Products Market Study

• The preference for creams among other beauty products – serums and gels – will remain high, owing to their easy availability and application. In addition, creams are an integral part of a daily beauty routine, and this is likely to offer sustainable supply opportunities to manufacturers.
• Though the anti-aging and anti-wrinkle products market has been a female-driven landscape, increasing look-consciousness among males is projected to add a new dimension to the existing sales scenario of the landscape.
• Critical moisturizing properties of hyaluronic acids are predicted to extend the frontiers of their application in anti-wrinkle gels, creams, and serums, during the forecast period.
• Consumers’ proclivity for facial care treatment will remain relatively high as compared to body care treatment. The sales of anti-aging and anti-wrinkle products through facial care treatment are expected to account for ~74% of the total share by 2027.

Need more information about Report Methodology? Click here- https://www.factmr.com/connectus/sample?flag=RM&rep_id=4337

• Manufacturers are adopting effective marketing strategies through powerful keywords, such as immediate, quick-fix, and instant, which have been found to be successful in drawing increased consumer attention.
• Brand-owned stores will remain robust distribution channels to disseminate information about new anti-aging and anti-wrinkle products; however, sales from online stores are projected to grow exponentially, as deals and discounts remain attractive features of this channel.

“High density of the generation X demography in China, which is the key target group, will retain the attractive quotient of the local anti-aging and anti-wrinkle products market. The presence of leading online channels will further drive profitability to the Chinese market during the forecast period”, opines a subject matter expert at Fact.MR.

Shift from Artificial Ingredients to Organic Products to Remain Profitable

The anti-aging and anti-wrinkle products market is fragmented in nature, with a handful of players leading at the international front, and facing intense competition from domestic players.

Full Access of this Exclusive Report is Available at- https://www.factmr.com/checkout/4337/S

Players in the anti-aging and anti-wrinkle products market, however, are facing headwinds from stringent regulatory norms, which is leading to frequent product recalls. Given this influence, manufacturers in the anti-aging and anti-wrinkle products market are increasing investments in research & development activities to launch new products. For instance, a key player – Clinique – announced the launch of a repair serum, which is suitable for all skin types, to control puffiness, and, in turn, slow the aging process.

Growing consciousness regarding the side effects of chemical-based products is leading to a shift in the raw materials being used for the production of anti-aging and anti-wrinkle products. Local players are developing products with organic ingredients to meet the unmet demands of consumers.

Find More Valuable Insights on Anti-aging and Anti-wrinkle Products Market

Fact.MR, in its new offering, brings to the fore an unbiased analysis of the global anti-aging and anti-wrinkle products market, presenting historical demand data (2017-2019), and forecast statistics for the period of 2020-2027. The study divulges compelling insights on the anti-aging and anti-wrinkle products market on the basis of product (serum, creams, gels, and others), gender (male and female), ingredient (retinoid, hyaluronic acids, alpha-hydroxy acids, and others), treatment (body care treatment and facial care treatment), and distribution channel (pharmacies, stores, and online stores), across five major regions.

About Fact.MR

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in the US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have in our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.

Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
E: sales@factmr.com
Website: https://www.factmr.com

The popularity of online pharmacies is growing at an unprecedented rate in the anticoagulants market, and these channels are projected to emerge as the standard distribution channel in the future. A rapid rise in sales from these channels is also attributable to the increasing demand for effective anticoagulant drugs in developing countries, which is influencing players in the anticoagulants market to target untapped countries with minimal investments in distribution establishments. However, frequent instances of patent expiry are offering a leeway to generic drugs, which is projected to impede the advancement of the anticoagulants market during the forecast period (2020-2026).

For detailed insights on enhancing your product footprint, request for a sample here- https://www.factmr.com/connectus/sample?flag=S&rep_id=4335

The aforementioned insights are explored comprehensively, along with accurate data, in an exclusive study published by Fact.MR. According to the report, the anticoagulants market is projected to trace a healthy growth trajectory, and grow ~1.6X during 2020-2026.

Key Takeaways of Anticoagulants Market Study

• The cost-effective attribute of conventional drugs, such as warfarin, is boosting consumers’ loyalty towards these drugs, thereby limiting the opportunities for anticoagulants.
• Producers are leveraging the prowess of quality development by zooming in their focus on the development of products with fewer to nil side effects, as anticoagulants are found to have caused nausea, vomiting, and excessive bleeding in some patients.
• The introduction of patient-assistance programs by leading players to cushion the high finances required for the production of anticoagulant drugs is expected to serve as an instrument to strategize customer acquisition and retention. Daiichi Sankyo—a leading player in the anticoagulants market—illustrates this strategy. The company offers the SAVAYSA Savings Card to eligible patients at US$ 4 for a 30-day prescription, and US$ 12 for a 90-day prescription.

Need more information about Report Methodology? Click here- https://www.factmr.com/connectus/sample?flag=RM&rep_id=4335

• The oral route of drug administration remains the standard method, with an estimated share of ~54% in 2020, in the anticoagulants market. Concerns regarding the sterilization of needles leading to contagious diseases and infections are offering an edge to the oral consumption of drugs.
• Factor XA Inhibitors accounted for ~50% share in the anticoagulants market in 2019, and are likely to retain their dominance in the drug class during 2020-2026. These drugs do not have any food interactions, owing to minimal metabolism through the CYP450 system.

“Untapped markets with high RoI potential in the anticoagulants market—India, China, South Africa, Mexico, and Brazil—are worth exploring to reduce overhead cost, and, in turn, gain a price competitive advantage without squeezing profit margins”, recommends a seasoned analyst at Fact.MR.

Market Majors Develop Blockbuster Drugs; Local Players Rely on Generic Drugs

Despite the growing popularity of blockbuster drugs, the threat of patent expiration is a cause of high concern among players in the anticoagulants market, which necessitates efforts and capital in research & development activities. The introduction of effective drugs remains the key strategy of leading players particularly, as the production of generic drugs by local and regional players hard-hits the revenue of these players. A leading player, Boehringer Ingelheim GmbH, announced the launch of a research & development program to explore its capabilities, increase number of pipeline drugs, and, in turn, collaborate with external partners. However, as novel drugs are cost-prohibitive in nature, small- and mid-level players are expanding in the anticoagulants market through the introduction of generic drugs.

Full Access of this Exclusive Report is Available at- https://www.factmr.com/checkout/4335/S

Find More Valuable Insights on Anticoagulants Market

Fact.MR, in its new offering, brings to the fore an unbiased analysis of the global anticoagulants market, presenting historical demand data (2016-2019), and forecast statistics for the period of 2020-2026. The study divulges compelling insights on the anticoagulants market on the basis of Drug Class (Factor XA Inhibitors (NOAC/DOAC), Heparins, Direct Thrombin Inhibitors, and Vitamin K Antagonists),  Indication (Deep Vein Thrombosis, Pulmonary Embolism, Atrial Fibrillation & Heart Attack, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Route of Administration (Oral and Injectable), across five major regions.

About Fact.MR

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in the US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have in our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.

Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
E: sales@factmr.com
Website: https://www.factmr.com